Endothelial-monocyte activating polypeptide II, a novel antitumor cytokine that suppresses primary and metastatic tumor growth and induces apoptosis in growing endothelial cells

Journal of Experimental Medicine

Volumn 190, Issue 3, 1999, Pages 341-353

  Schwarz, Margaret A ^a,b,f   Kandel, Jessica ^a   Brett, Jerald ^a   Li, Jun ^a   Hayward, Joanne ^c   Schwarz, Roderich E ^d,g   Chappey, Olivier ^e   Wautier, Jean Luc ^e   Chabot, John ^a   Lo Gerfo, Paul ^a   Stern, David ^a  

^a College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c GENENTECH INC   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Blood vessels; Capillary endothelium; Cell growth inhibitors; Programmed cell death; Tumor

Indexed keywords

ANGIOGENESIS INHIBITOR; CYTOKINE; ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; RECOMBINANT ENDOTHELIAL MONOCYTE ACTIVATING POLYPEPTIDE II; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LEWIS CARCINOMA; METASTASIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CATTLE; CELL DIVISION; CELLS, CULTURED; CYTOKINES; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; GROWTH INHIBITORS; HUMANS; INFUSIONS, INTRAVENOUS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PHYSIOLOGIC; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0033517112     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.190.3.341     Document Type: Article

References (51)

1. Old, L. 1986. Tumor necrosis factor. Science. 230:630-632.
2. Old, L., B. Benacerraf, D. Clarke, E. Carswell, and E. Stockert. 1961. Role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res. 21:1281-1300.
3. Clauss, M., C. Murray, M. Vianna, R. deWaal, G. Thurston, P. Nawroth, H. Gerlach, M. Gerlach, R. Bach, P. Familletti, and D. Stern. 1990. A polypeptide factor produced by fibrosarcoma cells that induces endothelial tissue factor and enhances the procoagulant response to TNF. J. Biol. Chem. 265:7078-7083.
4. Clauss, M., M. Gerlach, H. Gerlach, J. Brett, F. Wang, Y.-C. Pan, P. Familletti, J. Olander, D. Connolly, and D. Stern. 1990. VPF: a tumor-derived polypeptide which induces endothelial cell and monocyte procoagulant activity and promotes monocyte migration. J. Exp. Med. 172:1535-1545.
5. Kao, J., J. Brett, G. Godman, J. Chen, P. Familletti, J. Wang, Y.-C. Pan, D. Stern, and M. Clauss. 1992. Endothelial-monocyte activating polypeptide (EMAP) II. J. Biol. Chem. 267:20239-20247.
6. Kao, J., K. Houck, Y.-G. Fan, J. Brett, I. Haehnel, M. Kayton, T. Grickscheit, S. Libutti, J. Chabot, R. Nowgrod, et al. 1994. Characterization of a novel tumor-derived cytokine: EMAP II. J. Biol. Chem. 269:25106-25119.
7. Sherry, B., and A. Cerami. 1988. TNF exerts endocrine, paracrine, and autocrine control of inflammatory responses. J. Cell Biol. 107:1269-1277.
8. Dinarello, C., and C. Wolff. 1993. The role of interleukin 1 in disease. N. Engl. J. Med. 328:106-113.
9. Gerlach, H., H. Lieberman, R. Bach, G. Godman, J. Brett, and D. Stern. 1989. Enhanced responsiveness of endothelium in the growing/motile state to TNF. J. Exp. Med. 170: 913-931.
10. Gown, A., A. Vogel, D. Gordon, and P. Lu. 1985. A smooth muscle cell-specific monoclonal antibody recognizes smooth muscle actin isozymes. J. Cell Biol. 100:807-813.
11. Shreeniwas, R., S. Ogawa, F. Cozzolino, G. Torcia, N. Braunstein, C. Butura, J. Brett, H. Lieberman, M. Furie, J. Joseph-Silverstein, and D. Stern. 1991. Macrovascular and microvascular endothelium during long-term hypoxia: alterations in cell growth, monolayer permeability, and cell surface coagulant properties. J. Cell Physiol. 146:8-17.
12. Vaitukatis, J. 1981. Production of antisera with small doses of immunogen: multiple intradermal injections. Methods Enzymol 73:46-52.
13. Neeper, M., A.-M. Schmidt, J. Brett, S.-D. Yan, F. Wang, Y.-C. Pan, K. Elliston, D. Stern, and A. Shaw. 1992. Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267:14998-15004.
14. Kleinman, H., M. McGarvey, J. Hassell, V. Star, F. Cannon, G. Laurie, and G. Martin. 1986. Basement membrane complexes with biological activity. Biochemistry. 25:312-318.
15. Passaniti, A., R. Taylor, R. Pili, Y. Guo, P. Long, J. Haney, R. Pauly, D. Grant, and G. Martin. 1992. A simple quantitative method for assessing angiogenesis and anti-angiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67:519-527.
16. Kenyon, B., E. Voest, C. Chen, E. Flynn, J. Folkman, and R. D'Amato. 1996. A model of angiogenesis in the mouse cornea. Invest. Ophthalmol. Vis. Sci. 37:1625-1632.
17. 125I-containing acylating agent. Biochem. J. 133:529-539.
18. Yamoaka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.
19. Weast, R. 1966. Handbook of Chemistry and Physics. The Chemical Rubber Company, Cleveland, OH. 2,000 pp.
20. O'Reilly, M., L. Holmgren, Y. Shing, C. Chen, R. Rosenthal, M. Moses, W. Lane, Y. Cao, E. Sage, and J. Folkman. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:315-328.
21. Holmgren, L., M. O'Reilly, and J. Folkman. 1995. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1:149-153.
22. Fidler, I., and L. Ellis. 1994. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79:185-188.
23. Folkman, J. 1989. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82:4-6.
24. Folkman, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med. 1:27-31.
25. Murray, C. 1995. Tumour dormancy: not so sleepy after all. Nat. Med. 1:117-118.
26. Olive, P., and R. Durand. 1992. Detection of hypoxic cells in a murine tumor with the use of the comet assay. J. Natl. Cancer Inst. 84:707-711.
27. 31P MRS to monitor the induction of tumor hypoxia by the modification of the oxygen affinity of hemoglobin using BW589C. Int. J. Radiat. Oncol. Biol. Phys. 29:285-288.
28. Plate, K., G. Breier, H. Weich, and W. Risau. 1992. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature. 359:845-848.
29. Warren, R., H. Yuan, M. Matili, N. Gillett, and N. Ferrara. 1995. Regulation by VEGF of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J. Clin. Invest. 95:1789-1797.
30. Kim, J., B. Li, J. Winer, M. Armanini, N. Gillett, H. Phillips, and N. Ferrara. 1993. Inhibition of VEGF-induced angiogenesis suppresses tumor growth in vivo. Nature. 362:841-844.
31. Maciag, T., T. Mehlman, R. Friesel, and A. Schrieber. 1984. Heparin binds endothelial cell growth factor, the principal endothelial cell mitogen in bovine brain. Science. 225:932-935.
32. Shing, Y., J. Folkman, R. Sullivan, C. Butterfield, J. Murray, and M. Klagsbrun. 1984. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science. 223:1296-1298.
33. Fett, J., D. Strydom, R. Lobb, E. Alderman, J. Bethune, J. Riordan, and B. Vallee. 1985. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells. Biochemistry. 24:5480-5486.
34. King, T.V., and B. Vallee. 1991. Neovascularisation of the meniscus with angiogenin. An experimental study in rabbits. J. Bone Joint Surg. [Br.]. 73B:587-590.
35. Olson, K., T. French, B. Vallee, and J. Fett. 1994. A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice. Cancer Res. 54:4576-4579.
36. Kandel, J., E. Bossy-Wetzel, F. Ravanyi, M. Klagsbrun, J. Folkman, and D. Hanahan. 1991. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma. Cell. 66:1095-1104.
37. Hori, A., R. Sasada, E. Matsutani, K. Naito, Y. Sakura, T. Fujita, and Y. Kozai. 1991. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against bFGF. Cancer Res. 51:6189-6194.
38. Dameron, K., O. Volpert, M. Tainsky, and N. Bouck. 1994. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 265:1582-1585.
39. Van Meir, E., P. Polverini, V. Chazin, H.-J. Su Huang, N. de Tribolet, and W. Cavenee. 1994. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat. Genet. 8:171-176.
40. O'Reilly, M., L. Holmgren, C. Chen, and J. Folkman. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med. 2:689-692.
41. Shweiki, D., A. Itin, D. Soffer, and E. Keshet. 1992. VEGF induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature. 359:843-845.
42. Knighton, D., T. Hunt, H. Scheuenstuhl, B. Halliday, Z. Werb, and M. Banda. 1983. Oxygen tension regulates the expression of angiogenesis factor by macrophages. Science. 221:1283-1285.
43. Kuwabara, K., S. Ogawa, M. Matsumoto, S. Koga, M. Clauss, D. Pinsky, L. Witte, J. Joseph-Silverstein, M. Furie, G. Torcia, et al. 1995. Hypoxia-mediated induction of a/bFGF and PDGF in mononuclear phagocytes stimulates growth of hypoxic endothelial cells. Proc. Natl. Acad. Sci. USA. 92: 4606-4610.
44. Brogi, E., J. Winkles, R. Underwood, S. Clinton, G. Alberts, and P. Libby. 1993. Distinct patterns of expression of FGFs and their receptors in human atheroma and nonatherosclerotic arteries. J. Clin. Invest. 92:2408-2418.
45. Nawroth, P., D. Handley, G. Matsueda, R. DeWaal, H. Gerlach, D. Blohm, and D. Stern. 1988. Tumor necrosis factor/cachectin-induced intravascular fibrin formation in meth A fibrosarcomas. J. Exp. Med. 168:637-647.
46. Watanabe, N., Y. Niitsu, H. Umeno, H. Muriyama, H. Neda, N. Yamauchi, M. Maeda, and I. Urushizaki. 1988. Toxic effect of TNF on tumor vasculature in mice. Cancer Res. 48:2179-2183.
47. Freudenberg, N., K. Joh, O. Westphal, C. Mittermyer, M. Freudenberg, and C. Galanos. 1984. Haemorrhagic tumour necrosis following endotoxin administration. Virchows Arch. 403:377-389.
48. North, R., and E. Havell. 1988. The antitumor function of tumor necrosis factor (TNF) II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma. J. Exp. Med. 167:1086-1099.
49. Leibovich, S., P. Polverini, H. Shepard, D. Wiseman, V. Shively, and N. Nuseir. 1987. Macrophage-induced angiogenesis is mediated by TNF-α. Nature. 329:630-632.
50. Fraker-Schroder, M., W. Risau, R. Hallmann, P. Gautschi, and P. Bohlen. 1987. TNF-α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo. Prof. Natl. Acad. Sci. USA. 84:5277-5281.
51. Madri, J., L. Bell, and J. Merwin. 1992. Modulation of vascular cell behavior by TGFβ. Mol. Reprod. Dev. 32:121-126.